Gene Therapy Death Prompts Review of Adenovirus Vector

The impact of the death of Jesse Gelsinger on research into gene therapy is discussed. Gelsinger, a relatively fit 18-year-old with an inherited enzyme deficiency, died on Sep 17, 4 days after doctors injected a genetically altered virus into his liver.

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 286; no. 5448; pp. 2244 - 2245
Main Author Marshall, Eliot
Format Journal Article
LanguageEnglish
Published United States American Society for the Advancement of Science 17.12.1999
American Association for the Advancement of Science
The American Association for the Advancement of Science
Subjects
Adenoviruses, Human
Adenoviruses, Human - genetics
Adolescent
Advisory Committees
Clinical trials
Clinical Trials as Topic
Enzymes
Fatal Outcome
Fatalities
Gelsinger, Jesse
Gene therapy
Genetic Therapy - adverse effects
Genetic Vectors - adverse effects
Health aspects
Human adenoviruses
Humans
Immune system
Liver
Male
Medical research
Meetings
National Institutes of Health (U.S.)
News of the Week
Ornithine Carbamoyltransferase - genetics
Ornithine Carbamoyltransferase Deficiency Disease - therapy
Patients
Research Subjects
Resistance (Psychology)
United States
United States
Recombinant DNA Advisory Committee
University of Pennsylvania
Genetics and Reproduction
Biomedical and Behavioral Research
Online AccessGet full text

Cover

More Information
Summary:The impact of the death of Jesse Gelsinger on research into gene therapy is discussed. Gelsinger, a relatively fit 18-year-old with an inherited enzyme deficiency, died on Sep 17, 4 days after doctors injected a genetically altered virus into his liver.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-News-1
content type line 14
ObjectType-Case Study-2
ObjectType-News-3
content type line 23
ObjectType-Report-1
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0036-8075
1095-9203
DOI:10.1126/science.286.5448.2244